Brief: ADC Therapeutics Announces Encouraging Interim Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine Presented At The 16Th Annual International Conference On Malignant Lymphoma

ADC Therapeutics SA

22/06/2021 15:55

June 22 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * ADC THERAPEUTICS ANNOUNCES ENCOURAGING INTERIM RESULTS
FROM
PIVOTAL PHASE 2 CLINICAL TRIAL OF CAMIDANLUMAB TESIRINE (CAMI)
PRESENTED AT THE 16TH ANNUAL INTERNATIONAL CONFERENCE ON
MALIGNANT LYMPHOMA
    * ADC THERAPEUTICS SA - PHASE 2 SAFETY PROFILE, INCLUDING
INCIDENCE OF GBS, CONSISTENT WITH PHASE 1

Source text for Eikon:  urn:newsml:reuters.com:*:nBw3VK90Va
Further company coverage:  ADCT.N 

 ((Reuters.Briefs@thomsonreuters.com;))